It is now 30 years since the first report of a potent zinc-dependent histone deacetylase
(HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory …

Lysine (Lys) residues in proteins undergo a wide range of reversible post-translational
modifications (PTMs), which can regulate enzyme activities, chromatin structure, protein …

Histone deacetylase 8 (HDAC8) is a class I HDAC that catalyzes the deacetylation of histone
and non-histone proteins. As one of the best-characterized isoforms, numerous studies have …

Abstract Among different Histone deacetylases (HDACs), histone deacetylase 3 (HDAC3) is
an epigenetic drug target which is currently marked as a potential therapeutic strategy to …

We developed a first-in-class proteolysis targeting chimera (PROTAC) for selective
degradation of histone deacetylase 8 (HDAC8). The PROTAC induced degradation of …

Superior to linear peptides in biological activities, cyclic peptides are considered to have
great potential as therapeutic agents. To identify cyclic‐peptide ligands for therapeutic …

CRISPR/Cas9-mediated cleavage of DNA, which depends on the endonuclease activity of
Cas9, has been widely used for gene editing due to its excellent programmability and …

The acetylation of histone and non-histone proteins has been implicated in several disease
states. Modulation of such epigenetic modifications has therefore made histone …

Histone deacetylases (HDACs) are epigenetic enzymes which participate in transcriptional
repression and chromatin condensation mechanisms by removing the acetyl moiety from …

Colorectal cancer (CRC), the third most common cancer worldwide, remains highly lethal as
the disease only becomes symptomatic at an advanced stage. Growing evidence suggests …